Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nuvectis Pharma, Inc. - Common Stock (NQ: NVCT )

4.950 -0.780 (-13.61%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Nuvectis Pharma, Inc. - Common Stock

< Previous 1 2 3 Next >
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug
Nuvectis Pharma reports mixed Phase 1b results for NXP800 in ovarian cancer, showing antitumor activity and improved safety with adjusted dosing. 
Via Benzinga
S&P 500 Moves Lower; US Crude Oil Inventories Increase
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Dow Falls Over 100 Points; US Producer Prices Rise In October
Via Benzinga
Topics Stocks
Exposures US Equities
US Stocks Edge Lower; Cisco Earnings Top Views
Via Benzinga
Recap: Nuvectis Pharma Q3 Earnings
Via Benzinga
Nuvectis Pharma: Q1 Earnings Insights
Via Benzinga
From Nuvalent to Nuvectis Pharma: New Report Highlights NXP900's Synergy in NSCLC and Anticipated NXP800 Data Update
The report covers Nuvectis (NASDAQ: NVCT) alongside notable similar precision oncology players such as Nuvalent ($6.6B) and Summit Therapeutics ($15B). 
Via News Direct
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian
Summit Therapeutics' rise could signal emerging opportunities in precision oncology such Nuvectis Pharma (NASDAQ: NVCT), Silexion (NASDAQ:SLXN), and Scorpion leading the charge. 
Via News Direct
Could Nuvectis Pharma be the Next Summit Therapeutics? A New Report Highlights NXP900's Approach to NSCLC Treatment
Report spotlights Nuvectis Pharma's (NASDAQ: NVCT) NXP900 as a potential game-changer in NSCLC treatment, noting its unique mechanism targeting SRC/YES1 kinases and promising preclinical data 
Via News Direct
Nuvectis Pharma Rises in Pre-Market Following FDA Orphan Drug Designation for NXP800, Fueling Optimism Ahead of Key Clinical Data
Nuvectis Pharma Rises in Pre-Market Following FDA Orphan Drug Designation for NXP800, Fueling Optimism Ahead of Key Clinical Data 
Via News Direct
Exposures Product Safety
7 Penny Biotech Stocks to Triple Your Investment
Biotech penny stocks offer the chance to triple your investments and require an appetite for risk in order to capture returns. 
Via InvestorPlace
NVCT Stock Earnings: Nuvectis Pharma Beats EPS for Q1 2024
NVCT stock results show that Nuvectis Pharma beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
5 Healthcare Stocks to Buy for 2024
Healthcare stocks have been some of the top performers in 2024, and thanks to the potential of AI, these names will just keep heating up. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
NVCT Stock Earnings: Nuvectis Pharma Misses EPS for Q4 2023
NVCT stock results show that Nuvectis Pharma missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
10 Short Squeeze Stocks To Watch: Blue Apron, Intuitive Machines, Yellow Corp, Getty Images And More
Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a new focus of traders looking for the next huge move. High short interest and steep borrowing costs are among... 
Via Benzinga
Insiders Buying Texas Capital Bancshares And 3 Other Stocks
Although U.S. stocks closed lower on Thursday, there were a few notable insider trades. 
Via Benzinga
Insiders Buying Steel Connect And 2 Other Stocks
Although US stocks closed mixed on Thursday, there were a few notable insider trades. 
Via Benzinga
Insiders Buying Nuvectis Pharma And 2 Other Stocks
Although US stocks closed mostly higher on Wednesday, there were a few notable insider trades. 
Via Benzinga
Insiders Buying Joint Corp And 2 Other Stocks
Although US stocks closed higher on Tuesday, there were a few notable insider trades. 
Via Benzinga
Insiders Buying BranchOut Food And 2 Other Stocks
Although US stocks closed higher for the fourth session in a row, there were a few notable insider trades. 
Via Benzinga
Insiders Buying Asana And 2 Other Stocks
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.... 
Via Benzinga
More Than $3M Bet On Asana? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed higher on Monday, there were a few notable insider trades. 
Via Benzinga
$1M Bet On Children's Place? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed lower on Thursday, there were a few notable insider trades. 
Via Benzinga
Over $2M Bet On This Financial Services Stock? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed lower on Friday, there were a few notable insider trades. 
Via Benzinga
Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday
Gainers Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) shares surged 94.3% to close at $1.69 on Tuesday after the company filed a request for the withdrawal of the Registration Statement on Form S-1. 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.